Xiao Wenjing, Jiang Wenjie, Chen Zheng, Huang Yu, Mao Junyi, Zheng Wei, Hu Yonghe, Shi Jianyou
Department of Pharmacy, The General Hospital of Western Theater Command, Chengdu, 610083, China.
Department of Pharmacy, Personalized Drug Therapy Key Laboratory of Sichuan Province, Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, 610072, China.
Signal Transduct Target Ther. 2025 Mar 5;10(1):74. doi: 10.1038/s41392-024-02107-5.
The successful approval of peptide-based drugs can be attributed to a collaborative effort across multiple disciplines. The integration of novel drug design and synthesis techniques, display library technology, delivery systems, bioengineering advancements, and artificial intelligence have significantly expedited the development of groundbreaking peptide-based drugs, effectively addressing the obstacles associated with their character, such as the rapid clearance and degradation, necessitating subcutaneous injection leading to increasing patient discomfort, and ultimately advancing translational research efforts. Peptides are presently employed in the management and diagnosis of a diverse array of medical conditions, such as diabetes mellitus, weight loss, oncology, and rare diseases, and are additionally garnering interest in facilitating targeted drug delivery platforms and the advancement of peptide-based vaccines. This paper provides an overview of the present market and clinical trial progress of peptide-based therapeutics, delivery platforms, and vaccines. It examines the key areas of research in peptide-based drug development through a literature analysis and emphasizes the structural modification principles of peptide-based drugs, as well as the recent advancements in screening, design, and delivery technologies. The accelerated advancement in the development of novel peptide-based therapeutics, including peptide-drug complexes, new peptide-based vaccines, and innovative peptide-based diagnostic reagents, has the potential to promote the era of precise customization of disease therapeutic schedule.
基于肽的药物的成功获批可归因于多学科的协同努力。新型药物设计与合成技术、展示文库技术、递送系统、生物工程进展以及人工智能的整合，显著加速了具有开创性的基于肽的药物的开发，有效解决了与其特性相关的障碍，如快速清除和降解、需要皮下注射导致患者不适增加等问题，并最终推动了转化研究工作。目前，肽被用于多种医疗状况的管理和诊断，如糖尿病、减肥、肿瘤学和罕见病，此外，在促进靶向给药平台以及基于肽的疫苗的研发方面也越来越受到关注。本文概述了基于肽的治疗药物、递送平台和疫苗的当前市场及临床试验进展。通过文献分析探讨了基于肽的药物开发的关键研究领域，强调了基于肽的药物的结构修饰原则以及筛选、设计和递送技术的最新进展。新型基于肽的治疗药物的加速发展，包括肽 - 药物复合物、新型基于肽的疫苗和创新的基于肽的诊断试剂，有可能推动疾病治疗方案精准定制的时代。
